SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid concerns of a potential government shutdown, with the community debating its impact on the market. Some traders believe a shutdown is already priced in, while others anticipate a significant downturn. Broader discussions include potential rate cuts, market manipulation, and the overall economic outlook.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending following news that BlueBird 6 is ready for flight and will be shipped to India in October, kicking off the next-gen launch campaign. The community is actively discussing potential short squeezes and the possibility of the stock reaching new all-time highs, while also debating the impact of potential competition in the satellite communication sector. Some investors believe the stock is undervalued, while others are waiting for further confirmation of launch dates and partnerships.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending with a bullish sentiment as the community notes resilient charts and accumulation patterns. Many see a breakout on the horizon, with buyers steadily building positions and support levels holding firm. The focus remains on the strength of the accumulation phase and potential for upward momentum.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas Corp is trending as the community discusses the confirmed U.S. government stake in the company and its Thacker Pass project, anticipating fresh highs. Community members are weighing the impact of potential government shutdowns and are speculating about future contracts with companies like Tesla. Investors are closely watching price movements and debating whether to hold or sell.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to a mix of factors, including Elon Musk canceling his subscription over concerns about transgender content in children's shows, sparking community debate about values and content choices. Some subscribers are canceling in protest, while others defend the platform, creating volatility. Additionally, there's speculation around potential movie tariffs and a possible acquisition of WBD, contributing to uncertainty and active discussion among investors.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors discuss the potential impact of a surprise earnings beat amid concerns about tariffs and a possible government shutdown. Community members are debating whether the stock can sustain its gains, with some anticipating a squeeze while others remain cautious about guidance and market conditions. Discussions also highlight Nike's strategic realignment in the sportswear market and rebounding running segment, contributing to the stock's current attention.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following news of a potential drug-pricing deal with the Trump administration and a $70 billion investment in US manufacturing, sparking mixed reactions across the community. While some investors express bullish sentiment and anticipate further upside, others question the financial implications of price cuts and increased domestic investment. Discussions also revolve around Pfizer's undervalued status and potential benefits from tariff exemptions, as well as the broader implications for the pharmaceutical sector.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as analysts raise price targets, citing robust AI demand and TSMC's strong market position, with Morgan Stanley setting the highest target on Wall Street. Community discussions highlight its importance in the AI supply chain and its relationships with major players like NVIDIA and Apple. The stock is also gaining attention due to unusual options activity, suggesting potential bullish sentiment.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending amid bullish sentiment in the AI sector, fueled by news of NVIDIA's supply chains and big tech's increasing AI investments; the community is discussing potential breakouts and gap fills, with some eyeing price targets. Discussions include merger acquisition hopes and technical analysis, while others express frustration over the stock's price action and await news of a new CFO. Some users point to the fact that big players are shorting SMCI as the reason it is not taking off, and are awaiting the day the shorts are forced to cover.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders discuss its recent strength and potential breakout, with some highlighting unusual options activity suggesting bullish sentiment. Community members are debating whether small caps will continue to outperform, while others point to potential resistance levels and the possibility of a pullback. The ETF's correlation with broader market trends and upcoming economic data are also key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Equity

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. It operates through the following geographical segments: Chinese Mainland, USA, and Other Regions. The company was founded by Yu Xia, Peng Zhang, Baiyong Li, and Zhongmin Wang in March 2012 and is headquartered in Zhongshan, China.

Akeso Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

AKESF
Akeso Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKESF News

AKESF Akeso Inc